Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions
With the progression of tumor treatment, the 5-year survival rate of breast cancer is close to 90%. Cardiovascular toxicity caused by chemotherapy has become a vital factor affecting the survival of patients with breast cancer. Anthracyclines, such as doxorubicin, are still some of the most effectiv...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223011691 |
| _version_ | 1797686855321255936 |
|---|---|
| author | Chunping Liu Huiqi Chen Sien Guo Qiaojing Liu Zhijun Chen Haiding Huang Qi Zhao Longmei Li Huan Cen Zebo Jiang Qiyuan Luo Xiaoling Chen Jiaxiong Zhao Wensheng Chen Phillip C. Yang Lei Wang |
| author_facet | Chunping Liu Huiqi Chen Sien Guo Qiaojing Liu Zhijun Chen Haiding Huang Qi Zhao Longmei Li Huan Cen Zebo Jiang Qiyuan Luo Xiaoling Chen Jiaxiong Zhao Wensheng Chen Phillip C. Yang Lei Wang |
| author_sort | Chunping Liu |
| collection | DOAJ |
| description | With the progression of tumor treatment, the 5-year survival rate of breast cancer is close to 90%. Cardiovascular toxicity caused by chemotherapy has become a vital factor affecting the survival of patients with breast cancer. Anthracyclines, such as doxorubicin, are still some of the most effective chemotherapeutic agents, but their resulting cardiotoxicity is generally considered to be progressive and irreversible. In addition to anthracyclines, platinum- and alkyl-based antitumor drugs also demonstrate certain cardiotoxic effects. Targeted drugs have always been considered a relatively safe option. However, in recent years, some random clinical trials have observed the occurrence of subclinical cardiotoxicity in targeted antitumor drug users, which may be related to the effects of targeted drugs on the angiotensin converting enzyme, angiotensin receptor and β receptor. The use of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and beta-blockers may prevent clinical cardiotoxicity. This article reviews the toxicity and mechanisms of current clinical anti-breast cancer drugs and proposes strategies for preventing cardiovascular toxicity to provide recommendations for the clinical prevention and treatment of chemotherapy-related cardiomyopathy. |
| first_indexed | 2024-03-12T01:10:38Z |
| format | Article |
| id | doaj.art-4c950e94526141ab87c816e156bd8de1 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-12T01:10:38Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-4c950e94526141ab87c816e156bd8de12023-09-14T04:52:50ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-10-01166115373Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directionsChunping Liu0Huiqi Chen1Sien Guo2Qiaojing Liu3Zhijun Chen4Haiding Huang5Qi Zhao6Longmei Li7Huan Cen8Zebo Jiang9Qiyuan Luo10Xiaoling Chen11Jiaxiong Zhao12Wensheng Chen13Phillip C. Yang14Lei Wang15State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China; Department of Cardiovascular Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China; Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangzhou 510080, Guangdong Province, China; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, ChinaState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, ChinaState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, ChinaState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, ChinaState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, ChinaState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, ChinaSchool of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, Guangdong Province, ChinaState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, ChinaState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, ChinaGuangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, Guangdong Province, ChinaHealth Science Center, Shenzhen University, Shenzhen 518060, Guangdong Province, ChinaSecond Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, ChinaState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, ChinaDepartment of Cardiovascular Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, ChinaCardiovascular Stem Cell (Yang) Laboratory, Stanford University School of Medicine, Stanford, CA 94305, USA; Corresponding author.State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China; Department of Cardiovascular Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China; Corresponding author at: State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China.With the progression of tumor treatment, the 5-year survival rate of breast cancer is close to 90%. Cardiovascular toxicity caused by chemotherapy has become a vital factor affecting the survival of patients with breast cancer. Anthracyclines, such as doxorubicin, are still some of the most effective chemotherapeutic agents, but their resulting cardiotoxicity is generally considered to be progressive and irreversible. In addition to anthracyclines, platinum- and alkyl-based antitumor drugs also demonstrate certain cardiotoxic effects. Targeted drugs have always been considered a relatively safe option. However, in recent years, some random clinical trials have observed the occurrence of subclinical cardiotoxicity in targeted antitumor drug users, which may be related to the effects of targeted drugs on the angiotensin converting enzyme, angiotensin receptor and β receptor. The use of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and beta-blockers may prevent clinical cardiotoxicity. This article reviews the toxicity and mechanisms of current clinical anti-breast cancer drugs and proposes strategies for preventing cardiovascular toxicity to provide recommendations for the clinical prevention and treatment of chemotherapy-related cardiomyopathy.http://www.sciencedirect.com/science/article/pii/S0753332223011691CardiomyopathyCardiotoxicityChemotherapyBreast cancerAnthracyclineTrastuzumab |
| spellingShingle | Chunping Liu Huiqi Chen Sien Guo Qiaojing Liu Zhijun Chen Haiding Huang Qi Zhao Longmei Li Huan Cen Zebo Jiang Qiyuan Luo Xiaoling Chen Jiaxiong Zhao Wensheng Chen Phillip C. Yang Lei Wang Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions Biomedicine & Pharmacotherapy Cardiomyopathy Cardiotoxicity Chemotherapy Breast cancer Anthracycline Trastuzumab |
| title | Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions |
| title_full | Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions |
| title_fullStr | Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions |
| title_full_unstemmed | Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions |
| title_short | Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions |
| title_sort | anti breast cancer induced cardiomyopathy mechanisms and future directions |
| topic | Cardiomyopathy Cardiotoxicity Chemotherapy Breast cancer Anthracycline Trastuzumab |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223011691 |
| work_keys_str_mv | AT chunpingliu antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT huiqichen antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT sienguo antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT qiaojingliu antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT zhijunchen antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT haidinghuang antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT qizhao antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT longmeili antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT huancen antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT zebojiang antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT qiyuanluo antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT xiaolingchen antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT jiaxiongzhao antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT wenshengchen antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT phillipcyang antibreastcancerinducedcardiomyopathymechanismsandfuturedirections AT leiwang antibreastcancerinducedcardiomyopathymechanismsandfuturedirections |